Contra-indicated in patients with a history of any of the following gold-induced disorders: anaphylactic reactions, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasia or other severe hematologic disorders.
Adverse reactions can occur months after therapy has been discontinued.
- TRADE NAMES: Aureotan; Aurolate; Aurothio; Miocrin; Myochrysine (Merck); Myocrisin (Sanofi-Aventis); Ridaura (Prometheus); Shiosol; Solganal (Schering); Tauredon
- INDICATIONS: Rheumatoid arthritis
- SYNONYM: auranofin; aurothioglucose
- CLASS: Disease-modifying antirheumatic drug (DMARD)
- HALF-LIFE: 5 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ACE inhibitors, Benazepril, Captopril, Cilazapril, Enalapril, Fosinopril, Lisinopril, Penicillamine, Phenytoin, Quinapril, Ramipril, Trandolapril
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
